

**THE IMMUNE DEFICIENCY FOUNDATION
OF AUSTRALIA LIMITED**

ACN: 117 585 976

**FINANCIAL REPORT
FOR THE YEAR ENDED 30 JUNE 2013**

THE IMMUNE DEFICIENCY FOUNDATION OF AUSTRALIA LIMITED
ACN 117 585 976

CONTENTS

Directors' Report	2
Auditor's Independence Declaration	5
Statement of Profit or Loss and Other Comprehensive Income	6
Statement of Financial Position	7
Statement of Changes in Equity	8
Statement of Cash Flows	9
Notes to the Financial Statements	10
Directors' Declaration	16
Auditor's Report	17

General Information

The financial report covers The Immune Deficiency Foundation of Australia Limited as an individual entity. The financial report is presented in Australian dollars, which is The Immune Deficiency Limited's functional and presentation currency.

The financial report consists of the financial statements, notes to the financial statements and the directors' declaration.

The Immune Deficiency Foundation of Australia Limited is a not for profit unlisted public company limited by guarantee.

The financial report was authorised for issue, in accordance with a resolution of directors on September 2013. The directors have the power to amend and reissue the financial report.

THE IMMUNE DEFICIENCY FOUNDATION OF AUSTRALIA LIMITED
ACN 117 585 976

DIRECTORS' REPORT

Your directors present their report together with the financial statements on the company for the financial year ended 30 June 2013.

Directors

The following persons were directors in office during the whole of the financial year and up to the date of this report unless otherwise stated:

Adam Friederich

Richard Price

Lara Alexander

Karl Bleasel (Retired 26 November 2012)

Christine Jeffery (non voting)

Melanie Wong

Jacqueline Murphy

David Gillis (Appointed 29 April 2013)

Linda Holdaway (Appointed 9 February 2013)

Information on Directors

Name:	Adam Friederich
Special responsibilities:	Board Chair
Qualifications:	Grad Cert (Mngmt) Grad Dip (Science, Com), CIII Public Sector Admin, CIII Public Sector Qual Mgmt, BSc,
Experience and expertise:	Grad Cert (Mngmt) Grad Dip (Science, Com), CIII Public Sector Admin, CIII Public Sector Qual Mgmt, BSc (Hons), Adam has 20 years' experience with not for profit boards, and has been a board member or office bearer with numerous NFP organisations. Adam also has more than 15 years' experience working with the Australian Public Service, where his responsibilities focus on governance issues, such as strategic and business planning, performance reporting, and financial and HR management.
Name:	Richard Price
Special responsibilities:	Deputy Chair Company Secretary
Qualifications:	BEng (Mining, Hons), MSc (Mineral Economics), M AusIMM
Experience and expertise:	Richard is a mining engineer with 10 years' experience in the mining industry and 5 years' experience in financial services. Richard has a Primary Immunodeficiency (PID) and lives in Perth.
Name:	Lara Alexander
Special responsibilities:	Chair Audit & Finance Committee
Qualifications:	CPA, BA Econ Studies (Hons)
Experience and expertise:	Lara has worked in the NFP sector for over 15 years, working in various senior management and executive roles with organisations such as St John Ambulance, Cancer Council, Save the Children, Bethesda Hospital and more recently in the aged care sector with

Presbyterian Care Tasmania. Lara's expertise is predominantly in areas such as finance and budgeting, management, human resources and payroll and fundraising.

Name: Christine Jeffery
Special responsibilities: Director (non voting)
Executive Officer
Qualifications: BSB60201 Adv Dip Bus Mgmt
TAE40110 Cert IV in Training & Assessment,
17849 SA Policies Procedures & Practices for Sustainability
Experience and expertise: Christine has 20 years' experience in Management and 10 years' experience in Education & Training. Christine joined the IDFA Board in 2011 and became Executive Officer in 2012. Christine is also a Board Member and Asia Pacific Representative of IPOPI (International Patient Organisation for Primary immunodeficiencies). She has an adult daughter with complex immune and autoimmune diseases.

Name: Dr Melanie Wong
Special responsibilities: Chair Medical Advisory Committee
Director
Qualifications: MBBs (Hons), PhD, FRACP, FRCPA
Experience and expertise: Senior staff specialist, Department of Allergy and Immunology, The Children's Hospital at Westmead
Director of the Immunology Laboratory and Head of the Immunodeficiency Service
President Elect, Australasian Society of Clinical Immunology and Allergy (ASCIA)
Board member, Allergy and Immunology Foundation of Australasia (AIFA)

Name: Linda Holdaway
Special responsibilities: Director
Qualifications: B Comm (Acc) Grad Dip (ICAA) CA
Experience and expertise: Linda is a qualified Chartered Accountant with 16 years' experience in accounting and finance, including 7 in professional practice and the last 9 as a finance executive across various industries, including fashion, media, retail, cosmetics and not for profit. Linda joined the Board in 2013.

Name: Jacqueline Murphy
Special responsibilities: Director
Qualifications: CPE Level 1 (Clinical Pastoral Education), Assoc Dip Christian Studies
Experience and expertise: Jacqueline has spent a number of years working as a sub-contract moderator online as well as establishing and facilitating self help support groups and community groups. She is also a qualified

Chaplain. Jacqueline has Primary Immunodeficiency (PID) and other complex medical issues.

Name: Dr David Gillis
Special responsibilities: Director
Qualifications: MBS BS (1st class Hons), FRACP, FRCPA
Experience and expertise: David is an Immunologist with 27 years' experience in the clinical management of primary Immunodeficiency in adults. He is also a pathologist with extensive experience in the testing for primary Immunodeficiency. David was a previous chairperson of the primary immunodeficiency committee of ASCIA and was chairman of the South Australian IVIG Users Group for many years .

Name: Dr Karl Bleasel
Special responsibilities: Director – retired 26 Nov 2012
Qualifications: MBBS BMedSc FRACP
Experience and expertise: Immunologist, Hobart

Company Secretary Richard Price

Meeting of Directors

During the year, 6 meetings of directors were held. Attendance by each director during the year was as follows:

Name	Number Eligible to Attend	Number Attended
Adam Friederich	6	6
Richard Price	6	5
Lara Alexander	6	6
Karl Bleasel	4	2
Christine Jeffery	6	6
Melanie Wong	6	6
Jacqueline Murphy	6	5
Linda Holdaway	3	3
David Gillis	2	1

Objectives

Promote an understanding of primary immune deficiencies within both the general and medical communities. We will do this through:

Awareness We work to increase PID awareness in the general and medical community.

Membership We acknowledge that unity is strength and our aim is to reach all Australians with PID.

Advocacy We will support and act for our members and their families.

Communication We will continue to develop and maintain our communication with members, their families, our stakeholders, partners and key alliances.

Strategy for achieving the objectives

IDFA has a Board approved Strategic Plan focusing on three main areas – Marketing, Operations and Finance. The Executive Officer is responsible for achieving IDFA objectives, and updates the Board regularly on achievements and general progress.

The strategy for achieving IDFA goals is through:

- ✦ **Communication:** visits, phone calls, emails, new website, newsletters, membership packs, IDFA information and membership brochures, booklets about Primary Immune Deficiencies, media releases, member stories, speaking at events and seminars, maintaining contact with Industry and government organisations and other Rare Disease organisations
- ✦ **Visibility:** IDFA Conferences, Industry Conferences, Rare disease meetings, Media
- ✦ **Compliance:** with government and regulatory authorities
- ✦ **Member Engagement:** teleconferencing, PID Chats, picnics, social get togethers, Mentors and Buddies, encouraging volunteers
- ✦ **Involvement:** Immunologists, Hospital infusion wards, Immunology Nurses, Industry Conferences, Allied Rare Disease groups, ASCIA (Australasian Society Clinical Immunology and Allergy), IPOPI (International Patient Organisation for Primary Immunodeficiencies)
- ✦ **Participation:** trade events – ASCIA, IPOPI, PPTA, IPPIC, Nurses Education days, Immunology Seminars
- ✦ **Fund raising:** IDFA uses a Fundraiser, International Entertainment, to raise funds on our behalf. This is through the selling of tickets to Shows (Magic Show, Razzamatazz and Circus Quirkus). Corporate clients purchase tickets for disadvantaged children to attend the shows
Funds are also raised by members and volunteers.
- ✦ **Sponsorship** - This financial year IDFA received financial support from:
 - ✦ FaHCSIA
 - ✦ CSL Behring
 - ✦ Baxter
 - ✦ OctapharmaSeeking sponsors (corporate or government) continues to be a priority and an important part of the Executive Officer's role.

Performance Measures

IDFA uses the following *Kaplan Norton* Balanced Scorecard Indicators:

- ✦ Customers
- ✦ Growth and Development
- ✦ Business Processes
- ✦ Financial Strategies

These are used to develop Key Performance Indicators based around the IDFA Goals and Strategic Focus areas. The performance measures are outlined in the table below.

Strategic Plan Focus		MARKETING		OPERATIONS	FINANCES
Balanced Scorecard Indicators		Customers	Growth & Development	Business Processes	Financial Strategies
Goals	Membership	Increase membership	Increase Fundraising volunteer force	Increase Member events (Public Speaking, fundraising)	Fund improved resources for member services
	Awareness	Increase direct communication with Health Professionals	Increase alliances with rare disease groups	Update Procedure Manual - Increase number of Business and IT processes	Fund improved resources for awareness
	Advocacy	Increase member access to practical advice and general coping skills	Continue face to face meetings with stakeholders relating to Advocacy issues	Increase applications for fundraising and grants	Fund improved resources for advocacy (Counselling costs, pumps etc)
	Communication	Increase communication to existing members	Continue face to face meetings with stakeholders	Review effectiveness of recently established communication tools (brochures, surveys, Facebook)	Fund improved resources for communication (member pack, brochures, conference and media promotions)

Performance Achievements

IDFA performance achievements for this year are:

Membership

- ✦ Increased membership by 107%
 - Members ↑93%
 - Professional Contacts ↑175%
 - Rare Disease Alliances ↑138%
 - Stakeholders ↑200%
- ✦ Increased Fundraising volunteer force by 300%
- ✦ Increased Member events by 129% (Public Speaking, fundraising)
- ✦ Funding for improved resources for member services
 - Total Donations Revenue: \$ 6041.02

Awareness

- ✦ Increased direct communication with Health Professionals by 150%
- ✦ Increased alliances with rare disease groups by 138%
- ✦ Updated Procedure Manual - Increase number of Business and IT processes by 150%

- * Funding for improved resources for awareness -
 - o Total Speakers Network Revenue \$ 5,200.00

Advocacy

- * Increased member access to practical advice and general coping skills by 213%
- * Continued face to face meetings with stakeholders relating to Advocacy issues 193%
- * Increased applications for fundraising and grants by 350%
- * Funding applications for improved resources for advocacy (Counselling costs, pumps etc)
 - o Total Fundraising Volunteers Revenue \$ 1879.90

Communication

- * Increased communication to existing members by 363%
- * Continued and increased face to face meetings with stakeholders by 193%
- * Review effectiveness of recently established communication tools (brochures, surveys, Facebook)
 - o IDFA Member survey - 293 members participated
 - o Hospital infusion wards/ Igi.V Educational Bear and Kit sent out -146
 - o Email members increased by 302%
 - o New Website hits March to June 2013: 612
 - o Facebook closed group membership increased by 67%
 - o National Conference held - 114 participants sponsored to attend
 - o No of PID brochures produced: 6
 - o No of Immunologist/Nurse/Allied Health professional Resources produced: 3
 - o SN Events: 7
 - o Fundraising events: 4
 - o Members stories in media:22
 - o Media releases: 3
 - o Participation in research studies/surveys: 3
- * Fund improved resources for communication (member pack, brochures, conference and media promotions)
 - o Total Grants revenue: \$50,565.62

Principal activities


The company's principal activity during the financial year was providing registered PID patients with practical, financial, emotional, medicinal and social support. No significant changes in the nature of this activity occurred during the financial year.

Contributions on winding up

In the event that the company being wound up, every member undertakes to contribute up to \$20 each.

On behalf of the directors:

Director 
 RICHARD PRICE

Director 
 VANA ALEXANDER


Dated this 26..... day of SEPTEMBER 2013

**THE IMMUNE DEFICIENCY FOUNDATION OF AUSTRALIA LIMITED
ACN 117 585 976**


**UNDER SECTION 307c OF THE CORPORATIONS ACT 2001
TO THE DIRECTORS OF THE IMMUNE DEFICIENCY FOUNDATION
OF AUSTRALIA LIMITED**

As auditor for the audit of The Immune Deficiency Foundation of Australia Limited for the year ended 30 June 2013, I declare that, to the best of my knowledge and belief, there have been:

- i. no contraventions of the independence requirements of the *Corporations Act 2001* in relation to the audit; and
- ii. no contraventions of any applicable code of professional conduct in relation to the audit.



M. D. Nicholaeff
Partner
Sydney, 6 October 2013



UHY Haines Norton
Chartered Accountants

THE IMMUNE DEFICIENCY FOUNDATION OF AUSTRALIA LIMITED
ACN 117 585 976

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 JUNE 2013

	Note	2013 \$	2012 \$
Revenue	3a	1,024,335	962,322
Expenses	3b	<u>(1,015,609)</u>	<u>(961,860)</u>
Surplus before income tax expense		8,726	462
Income tax expense		<u>-</u>	<u>-</u>
Surplus after income tax expense for the year attributable to the members of The Immune Deficiency Foundation of Australia Limited		8,726	462
Other comprehensive income for the year, net of tax		-	-
Total comprehensive income for the year attributable to the members of The Immune Deficiency Foundation of Australia Limited		<u>8,726</u>	<u>462</u>

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

THE IMMUNE DEFICIENCY FOUNDATION OF AUSTRALIA LIMITED
ACN 117 585 976

STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2013

	Note	2013 \$	2012 \$
ASSETS			
CURRENT ASSETS			
Cash and Cash equivalents	4	187,093	194,770
Receivable	5	1,848	5,507
Total Current Assets		<u>188,941</u>	<u>200,277</u>
NON CURRENT ASSETS			
Office Equipment	6	-	-
Total Non Current Assets		<u>-</u>	<u>-</u>
TOTAL ASSETS		<u>188,941</u>	<u>200,277</u>
LIABILITIES			
CURRENT LIABILITIES			
Accruals	7	8,394	15,232
Other		11,726	10,758
Employee Provisions		9,258	23,450
Total current liabilities		<u>29,378</u>	<u>49,440</u>
TOTAL LIABILITIES		<u>29,378</u>	<u>49,440</u>
NET ASSETS		<u>159,563</u>	<u>150,837</u>
EQUITY			
Retained Surpluses		<u>159,563</u>	<u>150,837</u>
TOTAL EQUITY		<u>159,563</u>	<u>150,837</u>

The above statement of financial position should be read in conjunction with the accompanying notes

THE IMMUNE DEFICIENCY FOUNDATION OF AUSTRALIA LIMITED
ACN 117 585 976

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2013

	Retained Surpluses	Total Equity
	\$	\$
Balance at 1 July 2011	150,375	150,375
Surplus after income tax expense for the year	462	462
Other comprehensive income, net of tax	-	-
Total comprehensive income for the year	<u>462</u>	<u>462</u>
Balance at 30 June 2012	<u><u>150,837</u></u>	<u><u>150,837</u></u>

	Retained Surpluses	Total Equity
	\$	\$
Balance at 1 July 2012	150,837	150,837
Surplus after income tax expense for the year	8,726	8,762
Other comprehensive income, net of tax	-	-
Total comprehensive income for the year	<u>8,726</u>	<u>8,762</u>
Balance at 30 June 2013	<u><u>159,563</u></u>	<u><u>159,563</u></u>

The above statement of changes in equity should be read in conjunction with the accompanying notes

THE IMMUNE DEFICIENCY FOUNDATION OF AUSTRALIA LIMITED
ACN 117 585 976

STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 JUNE 2013

	Note	2013 \$	2012 \$
Cash flows from operating activities			
Receipts from donations and grants		1,014,483	958,959
Payments to suppliers and employees		(1,035,671)	(1,002,144)
Interest received & other		13,511	3,778
Net cash from operating activities		<u>(7,677)</u>	<u>(39,409)</u>
Cash flows from investing activities			
Purchase of property, plant & equipment		-	-
Net cash from investing activities		<u>-</u>	<u>-</u>
Cash flows from financing activities			
Net cash from investing activities		<u>-</u>	<u>-</u>
Net increase / (decrease) in cash and cash equivalents		(7,677)	(39,409)
Cash and cash equivalents at the beginning of the financial year		194,770	234,177
Cash and cash equivalents at the end of the financial year	4	<u>187,093</u>	<u>194,770</u>

The above statement of cash flows should be read in conjunction with the accompanying notes

THE IMMUNE DEFICIENCY FOUNDATION OF AUSTRALIA LIMITED
ACN 117 585 976

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

1. Significant accounting policies

The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

New, revised or amending Accounting Standards and Interpretations adopted

The Immune Deficiency Foundation of Australia Limited ("The Foundation") has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ("AASB") that are mandatory for the current reporting period.

The Foundation early adopted AASB 1053 Application of Tiers of Australian Accounting Standards and AASB 2010-02 Amendments to Australian Standards arising from Reduced Disclosure Requirements and later amending Standards, as relevant. No other new, revised or amending Accounting Standards or Interpretation that are not mandatory have been early adopted.

Any significant impact on the accounting policies of the Foundation from the adoption of these Accounting Standards and Interpretations are disclosed in the relevant accounting policy. The adoption of the Accounting Standards and Interpretations did not have any significant impact on the financial performance or financial position of the company.

The following Accounting Standards and Interpretation are most relevant to the company:

AASB 1053 – Application of Tiers of Australian Accounting Standards

The company has early adopted AASB 1053. This standard establishes a differential financial reporting framework consisting of two Tiers of reporting requirements for preparing general purpose financial statements, being Tier 1 Australian Accounting Standards and Tier 2 Australian Accounting Standards – Reduced Disclosure Requirements. The company being classed as Tier 2 continues to apply the full recognition and measurement requirements of Australian Accounting Standards with substantially reduced disclosures in accordance with AASB 2010-2 and later amending standards as relevant.

AASB 2010-2 – Amendments to Australian Accounting Standards arising from Reduced Disclosure Requirements

The company has adopted early AASB 2010-2. These amendments make numerous modification to a range of Australian Accounting Standards and Interpretations, to introduce reduced disclosure requirements to the pronouncements for application by certain types of entities in preparing general purpose financial statements. The adoption of these amendments has significantly reduced the Foundation's disclosure requirements.

Basis of Preparation

These general purpose financial statements have been prepared in accordance with the Australian Accounting Standards – Reduced Disclosure Requirements and Interpretations issued by the Australian Accounting Standards Board (AASB).

THE IMMUNE DEFICIENCY FOUNDATION OF AUSTRALIA LIMITED
ACN 117 585 976

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

The financial report has been prepared on an accruals basis and is based on historic costs. It does not take into account changing money values except where noted in the accounting policy notes. Cost is based on fair value of the consideration given in exchange for assets.

The financial report is presented in Australian dollars.

Critical Accounting Estimates

The preparation of the financial report in conformity with AASB's requires management to make judgements, estimates and assumption that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Revenue Recognition

Sponsorship and donations are recognised upon receipt.

Income Tax

The Foundation has been granted an exemption from paying income tax under Div 50 of the Income Tax Assessment Act 1997 and accordingly does not provide for income tax.

Cash and Cash Equivalents

Cash and cash equivalents includes cash on hand, deposits held on call with financial institutions, other short term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

Accounts Payable

Trade payables and other accounts payable are recognised when the Foundation becomes obliged to make future payments resulting from the purchase of goods and services.

Goods and Services Tax ("GST")

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Tax Office.

THE IMMUNE DEFICIENCY FOUNDATION OF AUSTRALIA LIMITED
ACN 117 585 976

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

Employee Benefits

Provision is made for the entity's liability for employee benefits arising from services rendered by employees to balance sheet date.

Contributions are made by the entity to an employee superannuation fund and are charged as expenses when incurred.

Property, plant and equipment

Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Depreciation is calculated on a straight-line basis to write off the net cost of each item of office equipment over its expected useful life of 3-5 years. The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date.

An item of property, plant and equipment is derecognised upon disposal or when there is no future economic benefit to the company. Gains and losses between the carrying amount and the disposal proceeds are taken to profit and loss.

2. Critical Accounting Judgments and Assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgments and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results.

THE IMMUNE DEFICIENCY FOUNDATION OF AUSTRALIA LIMITED
ACN 117 585 976

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

	2013	2012
	\$	\$
3. Operating surplus		
The operating surplus has been determined after:		
a) Crediting as Income		
Operating Activities		
Donations and Sponsorships	1,010,824	958,545
Other Income	<u>13,511</u>	<u>3,777</u>
	<u>1,024,335</u>	<u>962,322</u>
b) Charging as Expense		
Remuneration of the auditors		
Auditing the accounts	6,000	6,500
Other services	<u>-</u>	<u>-</u>
	<u>6,000</u>	<u>6,500</u>
IE Promotional Director	377,768	364,961
IE Producers Share	<u>377,623</u>	<u>387,041</u>
Employee Benefit Expense	<u>120,492</u>	<u>107,160</u>
4. Cash		
Cash at bank	<u>187,093</u>	<u>194,770</u>
5. Trade receivable		
Receivables	<u>1,848</u>	<u>5,507</u>
6. Property, plant and equipment		
Office Equipment	-	3,163
Less Accumulated Depreciation	<u>-</u>	<u>(3,163)</u>
	<u>-</u>	<u>-</u>

THE IMMUNE DEFICIENCY FOUNDATION OF AUSTRALIA LIMITED
ACN 117 585 976

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

	2013	2012
	\$	\$
7. Accruals		
Audit & Accounting Fee	6,725	6,500
Other Accruals	<u>1,668</u>	<u>8,732</u>
	<u>8,393</u>	<u>15,232</u>

8. Commitments

Operating Leases

There are no operating lease commitments

Capital Expenditure Commitments

There are no capital expenditure commitments

9. Related party transactions

a) The names of the Directors who held office during the financial year are:

Chairman	Adam Friederich
Deputy Chairman	Richard Price
Chair Audit and Finance Committee	Lara Alexander
Directors	Karl Bleasel
	Christine Jeffery
	Melaine Wong
	Jacqueline Murphy
	David Gillis
	Linda Holdaway
Company Secretary	Richard Price

b) There were no transactions with related parties during the year

THE IMMUNE DEFICIENCY FOUNDATION OF AUSTRALIA LIMITED
ACN 117 585 976

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

10. Financial instruments

a) Interest Rate Risk

The Foundation has no interest bearing liabilities.

b) Foreign Exchange Risk

The company is not exposed to fluctuations in foreign currency.

c) Net Fair Values

For all assets and liabilities, the net fair value approximates their carrying value.

The aggregate net fair values and carrying amounts of financial assets and financial liabilities are disclosed in the statement of financial position and in the notes to the financial statements.

11. Members' guarantee

The Foundation is a company limited by guarantee.

Each member of the company guarantees its liabilities to the extent of \$20.00. The number of members at year end was 502 registered non voting and 20 voting.

12. Events subsequent to reporting date

There have been no reportable events since the end of the financial year.

13. Auditors remuneration

	2013 \$	2012 \$
Audit of the financial statements – UHY Haines Norton	6,725	6,500

THE IMMUNE DEFICIENCY FOUNDATION OF AUSTRALIA LIMITED
ACN 117 585 976


DIRECTORS DECLARATION


In the directors' opinion:

- the attached financial statement and notes thereto comply with the Corporations Act 2001, the Australian Accounting Standards – Reduced Disclosure Requirements, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes thereto give a true and fair view of the company's financial position as at 30 June 2013 and of its performance for the year ended on that date;
- there are reasonable grounds to believe that the Foundation will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 295(5)(a) of the Corporations Act 2001.

On behalf of the directors


.....
RICHARDS PRICE Director & Co. Sec.
PERTH 4 OCT 2013
Canberra


.....
Director
Launceston 26.09.13
.....

Independent auditor's report to the members of The Immune Deficiency Foundation of Australia Limited

Report on the Financial Report

We have audited the accompanying financial report of The Immune Deficiency Foundation of Australia Limited, which comprises the statement of financial position as at 30 June 2013, the statement of profit and loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration.

Directors' Responsibility for the Financial Report

The directors of the company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards – Reduced Disclosure Requirements and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on the financial report based on our audit. We conducted our audit in accordance with Australian Auditing Standards. Those standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance about whether the financial report is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation of the financial report that gives a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating the overall presentation of the financial report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Independence

In conducting our audit, we have complied with the independence requirements of the *Corporations Act 2001*.

Basis for Qualified Opinion

As is common for organisations of this type, it is not practicable for the Company to maintain an effective system of internal control over sponsorship and other fund raising activities until their initial entry in the accounting records. Accordingly, our audit in relation to income was limited to amounts recorded.

Qualified Audit Opinion

In our opinion, except for the possible effects of the matter described in the basis for qualified opinion paragraph, the financial report of The Immune Deficiency Foundation of Australia Limited is in accordance with the Corporations Act 2001, including:

- (a) giving a true and fair view of the company's financial position as at 30 June 2013 and of its performance for the year ended on that date; and
- (b) complying with Australian Accounting Standards – Reduced Disclosure Requirements and the *Corporations Regulations 2001*.



M. D. Nicholaeff
Partner
Sydney, 6 October 2013



UHY Haines Norton
Chartered Accountants